A new triplet therapy for revlimid-refractory multiple myeloma
eMediNexus, 09 November 2018
Based on the ELOQUENT-3 trial, the FDA has approved elotuzumab (Empliciti) in combination with pomalidomide (Pomalyst) and dexamethasone for the treatment of relapsed or refractory multiple myeloma. The trial showed that elotuzumab-treated patients had progression-free survival of 10.3 months compared with 4.7 months for those in the control group of pomalidomide and dexamethasone alone.
To continue reading this article
Continue reading your article with a eMediNexus account.